Holen Sie sich die Stockscreener-App
4.60
6.31%
-0.31
Handel nachbörslich:
4.62
0.02
+0.43%
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
Replimune Group stock (US76029N1063): insider selling and legal probe put focus on biotech story - AD HOC NEWS
Ridgeback Group Reports 6.25M Shares in Replimune (REPL) - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc.REPL - PR Newswire
Replimune group CAO sells $40,101 in common stock By Investing.com - Investing.com India
Replimune group CAO sells $40,101 in common stock - Investing.com
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune (REPL) accounting chief sells 7,894 shares to cover RSU taxes - Stock Titan
Tax-cover sale: Replimune (NASDAQ: REPL) CCO offloads 8,626 shares - Stock Titan
Replimune (REPL) director tax-related sale covers RSU withholding - Stock Titan
Replimune shares plunge 64% after FDA rejects melanoma treatment application, investors join fraud probe. - Pluang
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the ... - Caledonian Record
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
What's going on with Replimune stock on Tuesday? - MSN
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL SEC FilingsReplimune Group 10-K, 10-Q, 8-K Forms - Stock Titan
RTW Investments, R. Wong report 7.36M shares in Replimune (NASDAQ: REPL) - Stock Titan
REPL Technical Analysis | Trend, Signals & Chart Patterns | REPLIMUNE GROUP INC (NASDAQ:REPL) - ChartMill
Replimune surges day after FDA Commissioner Makary resigns - MSN
Opinion | The FDA and My Daughter’s Death From Cancer - WSJ
Micron Rallied 90% In A Month — These 10 Small‑Cap Stocks Blew Past It - Benzinga
REPL stock rallies in anticipation of FDA decision on skin cancer drug - MSN
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1 (NASDAQ:REPL) - Seeking Alpha
Replimune Group Stock Short Interest Rises to 50.44% - Moomoo
Suvretta (REPL) reports 4,221,836 shared holdings in Replimune (5.1%) - Stock Titan
Replimune (REPL) Stock Rises Amid FDA Commissioner Marty Makary's Departure - GuruFocus
Replimune Group stock (US76029N1063): FDA rejection of RP1 melanoma therapy draws backlash - AD HOC NEWS
REPLIMUNE GROUP SHARES ADD 3.2% AFTER NEARLY 22% GAIN IN PREVIOUS SESSION - Moomoo
TradingKey - TradingKey
Number of shareholders of Replimune Group, Inc. – LSX:A2JQN1 - TradingView
REPL Soars As Trump FDA Shake-Up Revives RP1 Hopes - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Replimune (REPL) Shares Surge on FDA Developments - GuruFocus
REPL Stock Jumps As Wall Street Journal Challenges FDA - StocksToTrade
Replimune shares surge on report Trump to dismiss FDA chief Makary - Investing.com Australia
The FDA, Replimune and Patients Like Me - WSJ
T. Rowe Price (REPL) files 13G/A showing 157,965 shares (0.2%) ownership - Stock Titan
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA - Streetwise Reports
How many employees work at Replimune Group? - reveliolabs.com
What's Going On With Replimune Stock On Tuesday? - Sahm
FDA Commissioner Makary defends agency’s decision on Replimune’s drug, CNBC reports - hi99.com
FDA head Makary defends drug application rejections amid criticism - Seeking Alpha
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):